Several alternative treatments exist, each with different dosing schedules, active ingredients, and therapeutic applications
Please see full study designs by clicking the link above
The number of people living with diabetes rose from 200 million in 1990 to 830 million in 2022, with the steepest rises in low- and middle-income countries
So the question is: Is there going to be increased pressure on the starting doses of tirzepatide and semaglutide? The restrictions on compounded GLP-1 products come as concerns about existing shortages are bubbling
**Cost does not include the subscription fees and clinical care, which vary depending on coverage
You may be eating well, staying active, and doing the things that once worked, yet the scale barely moves, or the results never seem to last